- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
672
Companies which are more than 50% undervalued based on analyst price target.
672 companies
Evotec
Market Cap: €1.0b
Operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
EVT
€5.86
7D
-2.4%
1Y
-1.4%
uniQure
Market Cap: US$1.2b
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$17.95
7D
9.9%
1Y
231.2%
Oneness Biotech
Market Cap: NT$36.4b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan.
4743
NT$76.20
7D
8.9%
1Y
-47.6%
Enliven Therapeutics
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
ELVN
US$20.15
7D
-0.6%
1Y
-6.0%
Nuvation Bio
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
NUVB
US$3.90
7D
31.3%
1Y
39.8%
Dynavax Technologies
Market Cap: US$1.2b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$10.06
7D
-0.6%
1Y
-8.8%
Structure Therapeutics
Market Cap: US$1.1b
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
GPCR
US$19.76
7D
3.2%
1Y
-48.5%
Sionna Therapeutics
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
SION
US$23.06
7D
-10.3%
1Y
n/a
GC Biopharma
Market Cap: ₩1.5t
A biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally.
A006280
₩131,000.00
7D
1.0%
1Y
-10.2%
ARS Pharmaceuticals
Market Cap: US$1.1b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.69
7D
-16.9%
1Y
-9.0%
Upstream Bio
Market Cap: US$1.1b
A clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
UPB
US$19.97
7D
16.6%
1Y
n/a
MiMedx Group
Market Cap: US$1.0b
Develops and distributes placental tissue allografts for various sectors of healthcare.
MDXG
US$7.14
7D
0.6%
1Y
16.1%
ORIC Pharmaceuticals
Market Cap: US$1.0b
A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.
ORIC
US$10.88
7D
6.4%
1Y
12.7%
Spyre Therapeutics
Market Cap: US$1.0b
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
SYRE
US$17.00
7D
3.1%
1Y
-39.2%
CorMedix
Market Cap: US$1.0b
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$12.80
7D
-10.8%
1Y
124.6%
Pharming Group
Market Cap: €871.5m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHARM
€1.29
7D
2.5%
1Y
96.3%
GNI Group
Market Cap: JP¥148.4b
Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally.
2160
JP¥2,671.00
7D
-0.7%
1Y
27.5%
Praxis Precision Medicines
Market Cap: US$970.0m
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$46.85
7D
2.9%
1Y
-13.3%
Atai Life Sciences
Market Cap: US$968.8m
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
ATAI
US$4.56
7D
-1.9%
1Y
273.8%
Taysha Gene Therapies
Market Cap: US$889.3m
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
TSHA
US$3.36
7D
15.1%
1Y
64.7%
Geron
Market Cap: US$880.5m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.40
7D
0%
1Y
-67.1%
Trevi Therapeutics
Market Cap: US$870.7m
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$7.23
7D
0.3%
1Y
133.2%
UroGen Pharma
Market Cap: US$869.8m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$18.88
7D
-2.9%
1Y
42.7%
GH Research
Market Cap: US$869.7m
Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.
GHRS
US$14.05
7D
1.5%
1Y
65.9%
Seegene
Market Cap: ₩1.2t
Manufactures and sells molecular diagnostics products worldwide.
A096530
₩25,850.00
7D
-0.4%
1Y
3.4%
Oculis Holding
Market Cap: US$856.2m
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.
OCS
US$17.16
7D
5.0%
1Y
43.1%
Immunome
Market Cap: US$853.0m
A clinical-stage biotechnology company, develops targeted cancer therapies.
IMNM
US$10.52
7D
10.6%
1Y
-22.3%
BridgeBio Oncology Therapeutics
Market Cap: US$850.7m
A clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients.
BBOT
US$10.08
7D
6.7%
1Y
-2.4%
Phathom Pharmaceuticals
Market Cap: US$835.8m
A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
PHAT
US$12.34
7D
1.3%
1Y
-30.4%
Laekna
Market Cap: HK$6.5b
An investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea.
2105
HK$17.05
7D
4.3%
1Y
251.5%
EyePoint Pharmaceuticals
Market Cap: US$827.1m
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
EYPT
US$11.88
7D
2.4%
1Y
47.4%
Anavex Life Sciences
Market Cap: US$804.0m
Operates as a biopharmaceutical company.
AVXL
US$9.40
7D
-2.5%
1Y
82.5%
Akebia Therapeutics
Market Cap: US$800.7m
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
AKBA
US$2.96
7D
-5.7%
1Y
119.3%
Iovance Biotherapeutics
Market Cap: US$799.7m
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
IOVA
US$2.20
7D
-1.3%
1Y
-79.0%
Akums Drugs and Pharmaceuticals
Market Cap: ₹70.5b
Manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally.
AKUMS
₹460.20
7D
1.3%
1Y
-46.8%
Dianthus Therapeutics
Market Cap: US$793.8m
A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
DNTH
US$26.50
7D
12.4%
1Y
-0.5%